QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
LON:N4P

N4 Pharma (N4P) Share Forecast, Price & News

GBX 2.88
-0.07 (-2.20%)
(As of 05/16/2022 04:00 PM ET)
Add
Compare
Today's Range
2.86
2.89
50-Day Range
2.20
3.90
52-Week Range
2.10
10.43
Volume
10,556 shs
Average Volume
920,475 shs
Market Capitalization
£5.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive N4P News and Ratings via Email

Sign-up to receive the latest news and ratings for N4 Pharma and its competitors with MarketBeat's FREE daily newsletter.

N4 Pharma logo

About N4 Pharma

N4 Pharma Plc, a specialist pharmaceutical company, develops novel silica nanoparticle delivery system for pharmaceutical and biotechnology companies in the United Kingdom. It develops Nuvec, a non-viral adjuvant delivery system for vaccines and cancer treatments. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Major
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Sales & Book Value

Annual Sales
£23.52 thousand
Cash Flow
GBX 0.98 per share
Book Value
GBX 1.20 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£5.22 million
Optionable
Not Optionable

Company Calendar

Last Earnings
9/17/2020
Today
5/16/2022

MarketRank

Overall MarketRank

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













N4 Pharma (LON:N4P) Frequently Asked Questions

How were N4 Pharma's earnings last quarter?

N4 Pharma Plc (LON:N4P) issued its quarterly earnings results on Thursday, September, 17th. The company reported ($0.48) earnings per share for the quarter.
View N4 Pharma's earnings history
.

Who are N4 Pharma's key executives?
N4 Pharma's management team includes the following people:
  • Mr. Nigel James Theobald, Founder, CEO & Exec. Director (Age 58, Pay $75k)
  • Dr. David Templeton, Exec. Director & Technical Director
  • Mr. Luke Sebastian Cairns, Exec. Director (Age 44, Pay $40k)
  • Rob Harris, Head of CMC Devel.
  • Dr. Andrew Leishman, Consultant
What other stocks do shareholders of N4 Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other N4 Pharma investors own include Intercede Group (IGP), Medpace (MEDP), Regeneron Pharmaceuticals (REGN), Sirius Minerals (SXX), SolGold (SOLG), Reach (RCH), Petra Diamonds (PDL), Interserve (IRV), Cornerstone Capital Resources (CGP) and Bushveld Minerals (BMN).

What is N4 Pharma's stock symbol?

N4 Pharma trades on the London Stock Exchange (LON) under the ticker symbol "N4P."

How do I buy shares of N4 Pharma?

Shares of N4P and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is N4 Pharma's stock price today?

One share of N4P stock can currently be purchased for approximately GBX 2.89.

How much money does N4 Pharma make?

N4 Pharma has a market capitalization of £5.22 million and generates £23.52 thousand in revenue each year.

How many employees does N4 Pharma have?

N4 Pharma employs 5 workers across the globe.

What is N4 Pharma's official website?

The official website for N4 Pharma is www.n4pharma.com.

How can I contact N4 Pharma?

N4 Pharma's mailing address is Weston House, 1 Bradgate Park View, DERBY, DE73 5UJ, United Kingdom. The company can be reached via phone at +44-1332-690061.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.